Quick Answer
Hyperbaric oxygen therapy for PTSD is an active area of research, particularly among combat veterans with co-occurring mild traumatic brain injury. Trials using 1.5 ATA have shown reductions in PTSD symptom severity and depression scores, while at least one trial using 2.4 ATA found no significant benefit over a sham control. PTSD is not an FDA-approved HBOT indication. Veterans considering this treatment should pursue it through a VA-affiliated research program or accredited clinical facility — not as a home wellness routine.
Why Veterans Are Asking About HBOT
PTSD affects an estimated 7–8% of the U.S. population at some point in their lives, and considerably more among combat veterans — some studies put the figure above 20% for those who served in recent conflicts. Standard treatments (trauma-focused psychotherapy, SSRIs) help many patients, but a meaningful subset don’t respond fully, and many veterans specifically deal with PTSD alongside mild traumatic brain injury from blast exposure — a combination that’s harder to treat with talk therapy or medication alone.
HBOT entered this conversation because of its neurological rationale: if blast-related brain injury contributes to PTSD symptom severity, and hyperbaric oxygen supports neurological recovery, then treating the physical injury might improve the psychiatric symptoms too. That’s a reasonable hypothesis — and it’s been tested.
What the Research Shows
| Harch et al. (2017), Journal of Neurotrauma | Veterans, mild TBI + PTSD | 1.5 ATA | Significant reduction in PTSD symptom severity and depression scores |
|---|---|---|---|
| Wolf et al. (2012), Journal of Neurotrauma | Active-duty military, mild TBI + PTSD | 2.4 ATA | No significant difference vs. sham-air control |
| Doenyas-Barak et al. (2022), PLOS ONE | Post-traumatic patients | 2.0 ATA | Reduced PTSD and depression symptoms; increased brain connectivity on imaging |
The pattern across these trials mirrors what shows up in TBI research generally (see our related article on HBOT for TBI): lower-pressure protocols (1.5–2.0 ATA) have produced more consistently positive results than the 2.4 ATA protocol used by Wolf et al., though researchers haven’t fully settled why. Some propose that structured rest and routine — independent of oxygen pressure — play a meaningful role in any 40-session protocol, which is exactly what sham-controlled trial designs are built to test.
What This Means If You’re Considering HBOT for PTSD
The published research uses clinical pressure equipment — hard-shell chambers at 1.5–2.4 ATA, delivered under medical or research supervision, often through VA-affiliated studies or academic programs. This is meaningfully different from mild hyperbaric equipment used in home and wellness settings.
| Pressure | 1.5–2.4 ATA | 1.1–1.7 atm |
|---|---|---|
| Setting | VA / research hospital | Home, wellness center |
| Supervision | Psychiatric + hyperbaric medical team | Self-administered |
| FDA status | Not approved; investigational | Not applicable |
| Access | VA referral, clinical trial enrollment | Direct purchase |
If you’re a veteran interested in the treatment studied in these trials, the appropriate path is talking to your VA provider about hyperbaric research programs — several VA medical centers have run or are currently running HBOT trials for PTSD and TBI. This is not something a home wellness chamber is built or positioned to replicate.
Where Mild HBOT Fits — Honestly
We build mild hyperbaric chambers, and we’re not going to tell you they treat PTSD — they’re not studied for that, and making that claim would be both inaccurate and against FDA/FTC guidance on medical device marketing. What mild HBOT does offer is a quiet, low-stimulation environment that some veterans use as part of a broader wellness and recovery routine — alongside, not instead of, evidence-based PTSD treatment like therapy and, where appropriate, clinical HBOT research programs.
The AURA One is designed for exactly this kind of calm, private daily use at home — ambient lighting, quiet operation under 50 dB, and a simple touchscreen interface that doesn’t require managing complicated settings during a session. For veteran service organizations or wellness centers building a broader recovery-support offering for multiple people, the TITAN Duo allows two-person sessions in a supervised setting.
Again: these are wellness tools, not a substitute for the trauma-focused psychiatric care or clinical HBOT research protocols that the studies above are actually testing.
FAQ
Q: Is HBOT an approved treatment for PTSD?
No. PTSD is not among the FDA’s approved indications for hyperbaric oxygen therapy. Clinical research is ongoing, primarily through VA-affiliated studies and academic trials, and results so far are promising but mixed.
Q: What pressure do PTSD clinical trials use?
Published trials range from 1.5 to 2.4 ATA, delivered in clinical hard-shell chambers — higher than the 1.1–1.7 atm range used in mild home and wellness chambers.
Q: How can veterans access clinical HBOT trials for PTSD?
Through a VA provider or by searching ClinicalTrials.gov for active PTSD/TBI hyperbaric oxygen studies. Eligibility and enrollment are managed through the research site directly.
Q: Can a mild hyperbaric chamber help manage PTSD symptoms at home?
There’s no published clinical evidence that mild HBOT (1.1–1.7 atm) treats PTSD. Some veterans use mild chambers as part of a general wellness routine alongside evidence-based psychiatric care, but this should not replace trauma-focused treatment.
This article is for educational purposes only and is not medical advice. PTSD is not an FDA-approved indication for HBOT. Veterans and anyone managing a PTSD diagnosis should consult a mental health provider and, if interested in hyperbaric research, their VA provider or an accredited clinical trial site. HyperbaricO2Care manufactures mild hyperbaric chambers (1.1–1.7 atm) intended for general wellness use and makes no claim that its equipment treats PTSD. If you are in crisis, contact the Veterans Crisis Line at 988, then press 1. References: Harch et al., Journal of Neurotrauma (2017); Wolf et al., Journal of Neurotrauma (2012); Doenyas-Barak et al., PLOS ONE (2022).
Explore our chambers: AURA One (Home) · TITAN Duo (Clinic) · View All Products